DDX17 and NLRC4 targeting inflammatory diseases

• Main Authors: AMBATI JOSEPH, AMBATI KASRA, WANG SHAOBIN
• Format: Patent
• Language: Chinese; English
• Published: 07.06.2022
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

Provided are methods for treating and/or preventing a disease, disorder, or condition associated with the biological activity of an inflammasome containing the NLR family CARD domain 4 (NLRC4). In some embodiments, the methods comprise administering to a subject in need thereof a composition comprising a nucleoside reverse transcriptase inhibitor (NRTI). Also provided are methods of inhibiting NLRC4-induced activation of caspase-1 in a cell, methods of inhibiting NLRC4-induced release of IL-1 [beta] from a cell, methods of inhibiting Alu-induced retinal pigment epithelial cell (RPE) denaturation in a subject, and compositions for use in the methods disclosed herein. 提供了用于治疗和/或预防与含有NLR家族CARD结构域4(NLRC4)的炎性体生物活性相关的疾病、障碍或病症的方法。在一些实施方式中，该方法包括向有需要的对象施用包含核苷逆转录酶抑制剂(NRTI)的组合物。还提供了抑制细胞中NLRC4诱导的胱天蛋白酶-1活化的方法、抑制NLRC4诱导的IL-1β从细胞释放的方法、抑制对象中Alu诱导的视网膜色素上皮细胞(RPE)变性的方法和用于本文公开方法的组合物。